Clinical Trial Update: TACE Combined With Lenvatinib and Sintilimab for Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of TACE with lenvatinib and sintilimab for non-resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)
• TACE

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: COMPLETED